Selected research
Industry Research
Antiangiogenic Drugs Industry Research Report 2026
Market perspective
The global Antiangiogenic Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Antiangiogenic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Antiangiogenic Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Antiangiogenic Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Antiangiogenic Drugs include Chia Tai Tianqing, Sanofi, Jiangsu Hengrui Pharmaceuticals, Simcere, Roche, Pfizer, Novartis, Janssen Biotech and Exelixis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Antiangiogenic Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antiangiogenic Drugs Market by Company
Chia Tai Tianqing
Sanofi
Jiangsu Hengrui Pharmaceuticals
Simcere
Roche
Pfizer
Novartis
Janssen Biotech
Exelixis
Eli Lilly
Eisai
Boehringer Ingelheim
Bayer
AstraZeneca
Antiangiogenic Drugs Segment by Type
Macromolecular Single-target Angiogenesis Inhibitor
Endogenous Pan-target Angiogenesis Inhibitor
Small Molecule Multi-target Angiogenesis Inhibitor
Antiangiogenic Drugs Segment by Application
Cancer Therapy
Inflammatory and Autoimmune Diseases
Ophthalmic Diseases
Other
Antiangiogenic Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiangiogenic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antiangiogenic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiangiogenic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Antiangiogenic Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Antiangiogenic Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Antiangiogenic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Macromolecular Single-target Angiogenesis Inhibitor
- Endogenous Pan-target Angiogenesis Inhibitor
- Small Molecule Multi-target Angiogenesis Inhibitor
Applications
- Cancer Therapy
- Inflammatory and Autoimmune Diseases
- Ophthalmic Diseases
- Other
Companies covered
- Chia Tai Tianqing
- Sanofi
- Jiangsu Hengrui Pharmaceuticals
- Simcere
- Roche
- Pfizer
- Novartis
- Janssen Biotech
- Exelixis
- Eli Lilly
- Eisai
- Boehringer Ingelheim
- Bayer
- AstraZeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Antiangiogenic Drugs Market Size (2021-2032)
- 2.2.2 Global Antiangiogenic Drugs Sales (2021-2032)
- 2.2.3 Global Antiangiogenic Drugs Market Average Price (2021-2032)
- 2.3 Antiangiogenic Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Macromolecular Single-target Angiogenesis Inhibitor
- 2.3.3 Endogenous Pan-target Angiogenesis Inhibitor
- 2.3.4 Small Molecule Multi-target Angiogenesis Inhibitor
- 2.4 Antiangiogenic Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Cancer Therapy
- 2.4.3 Inflammatory and Autoimmune Diseases
- 2.4.4 Ophthalmic Diseases
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Antiangiogenic Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Antiangiogenic Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Antiangiogenic Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Antiangiogenic Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Antiangiogenic Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Antiangiogenic Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Antiangiogenic Drugs, Product Type & Application
- 3.8 Global Manufacturers of Antiangiogenic Drugs, Established Date
- 3.9 Global Antiangiogenic Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Chia Tai Tianqing
- 4.1.1 Chia Tai Tianqing Company Information
- 4.1.2 Chia Tai Tianqing Business Overview
- 4.1.3 Chia Tai Tianqing Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Chia Tai Tianqing Antiangiogenic Drugs Product Portfolio
- 4.1.5 Chia Tai Tianqing Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Antiangiogenic Drugs Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Jiangsu Hengrui Pharmaceuticals
- 4.3.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 4.3.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 4.3.3 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product Portfolio
- 4.3.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 4.4 Simcere
- 4.4.1 Simcere Company Information
- 4.4.2 Simcere Business Overview
- 4.4.3 Simcere Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Simcere Antiangiogenic Drugs Product Portfolio
- 4.4.5 Simcere Recent Developments
- 4.5 Roche
- 4.5.1 Roche Company Information
- 4.5.2 Roche Business Overview
- 4.5.3 Roche Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Roche Antiangiogenic Drugs Product Portfolio
- 4.5.5 Roche Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Antiangiogenic Drugs Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Novartis
- 4.7.1 Novartis Company Information
- 4.7.2 Novartis Business Overview
- 4.7.3 Novartis Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Novartis Antiangiogenic Drugs Product Portfolio
- 4.7.5 Novartis Recent Developments
- 4.8 Janssen Biotech
- 4.8.1 Janssen Biotech Company Information
- 4.8.2 Janssen Biotech Business Overview
- 4.8.3 Janssen Biotech Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Janssen Biotech Antiangiogenic Drugs Product Portfolio
- 4.8.5 Janssen Biotech Recent Developments
- 4.9 Exelixis
- 4.9.1 Exelixis Company Information
- 4.9.2 Exelixis Business Overview
- 4.9.3 Exelixis Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Exelixis Antiangiogenic Drugs Product Portfolio
- 4.9.5 Exelixis Recent Developments
- 4.10 Eli Lilly
- 4.10.1 Eli Lilly Company Information
- 4.10.2 Eli Lilly Business Overview
- 4.10.3 Eli Lilly Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Eli Lilly Antiangiogenic Drugs Product Portfolio
- 4.10.5 Eli Lilly Recent Developments
- 4.11 Eisai
- 4.11.1 Eisai Company Information
- 4.11.2 Eisai Business Overview
- 4.11.3 Eisai Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Eisai Antiangiogenic Drugs Product Portfolio
- 4.11.5 Eisai Recent Developments
- 4.12 Boehringer Ingelheim
- 4.12.1 Boehringer Ingelheim Company Information
- 4.12.2 Boehringer Ingelheim Business Overview
- 4.12.3 Boehringer Ingelheim Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Boehringer Ingelheim Antiangiogenic Drugs Product Portfolio
- 4.12.5 Boehringer Ingelheim Recent Developments
- 4.13 Bayer
- 4.13.1 Bayer Company Information
- 4.13.2 Bayer Business Overview
- 4.13.3 Bayer Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Bayer Antiangiogenic Drugs Product Portfolio
- 4.13.5 Bayer Recent Developments
- 4.14 AstraZeneca
- 4.14.1 AstraZeneca Company Information
- 4.14.2 AstraZeneca Business Overview
- 4.14.3 AstraZeneca Antiangiogenic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 AstraZeneca Antiangiogenic Drugs Product Portfolio
- 4.14.5 AstraZeneca Recent Developments
5 Global Antiangiogenic Drugs Market Scenario by Region
- 5.1 Global Antiangiogenic Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Antiangiogenic Drugs Sales by Region: 2021-2032
- 5.2.1 Global Antiangiogenic Drugs Sales by Region: 2021-2026
- 5.2.2 Global Antiangiogenic Drugs Sales by Region: 2027-2032
- 5.3 Global Antiangiogenic Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Antiangiogenic Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Antiangiogenic Drugs Revenue by Region: 2027-2032
- 5.4 North America Antiangiogenic Drugs Market Facts & Figures by Country
- 5.4.1 North America Antiangiogenic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Antiangiogenic Drugs Sales by Country (2021-2032)
- 5.4.3 North America Antiangiogenic Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Antiangiogenic Drugs Market Facts & Figures by Country
- 5.5.1 Europe Antiangiogenic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Antiangiogenic Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Antiangiogenic Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Antiangiogenic Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Antiangiogenic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Antiangiogenic Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Antiangiogenic Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Antiangiogenic Drugs Market Facts & Figures by Country
- 5.7.1 South America Antiangiogenic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Antiangiogenic Drugs Sales by Country (2021-2032)
- 5.7.3 South America Antiangiogenic Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Antiangiogenic Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Antiangiogenic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Antiangiogenic Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Antiangiogenic Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Antiangiogenic Drugs Sales by Type (2021-2032)
- 6.1.1 Global Antiangiogenic Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Antiangiogenic Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Antiangiogenic Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Antiangiogenic Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Antiangiogenic Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Antiangiogenic Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Antiangiogenic Drugs Sales by Application (2021-2032)
- 7.1.1 Global Antiangiogenic Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Antiangiogenic Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Antiangiogenic Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Antiangiogenic Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Antiangiogenic Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Antiangiogenic Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Antiangiogenic Drugs Value Chain Analysis
- 8.1.1 Antiangiogenic Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Antiangiogenic Drugs Production Mode & Process
- 8.2 Antiangiogenic Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Antiangiogenic Drugs Distributors
- 8.2.3 Antiangiogenic Drugs Customers
9 Global Antiangiogenic Drugs Analyzing Market Dynamics
- 9.1 Antiangiogenic Drugs Industry Trends
- 9.2 Antiangiogenic Drugs Industry Drivers
- 9.3 Antiangiogenic Drugs Industry Opportunities and Challenges
- 9.4 Antiangiogenic Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst